The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad. 

Users expressed concern that Illumina would have an even tighter grip on the sequencing market but are optimistic that it would spur development of PacBio's technology.

The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.

The BioFire FilmArray Pneumonia Panel was cleared by the FDA while the BioFire FilmArray Pneumonia Panel Plus was CE marked.

GWAS summary statistics data led to three main loci with ties to both Alzheimer's and cardiovascular disease, with additional enrichment at lipid-related sites.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Clinical laboratories are increasingly adopting molecular assays as an alternative to the tedious, time-consuming stool cultures that have long been the mainstay for testing patients who might have infectious diarrhea or conditions such as Salmonella or Campylobacter. With an estimated 1.7 billion cases of childhood diarrheal disease occurring annually around the world, this is a significant advance for gastroenteritis testing.

Learn about the scientific advancement of extracting cell-free DNA (cfDNA) from liquid biopsies in order to detect, treat and monitor cancer progression and therapy more accurately and effectively. 

Oct
25
Sponsored by
MNG Laboratories

Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.